BlackRock Declares Quarterly Dividend of $5.73 on Common Stock

BlackRock Declares Quarterly Dividend of $5.73 on Common Stock

NEW YORK–(BUSINESS WIRE)–
BlackRock, Inc. (NYSE:BLK) today announced that its Board of Directors has declared a quarterly cash dividend of $5.73 per share of common stock, payable December 22, 2026 to shareholders of record at the close of business on December 8, 2026.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

Investor Relations

Caroline Rodda

212-810-3442

[email protected]

Media Relations

Patrick Scanlan

212-810-3622

[email protected]

 

 

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Walker & Dunlop Arranges $270 Million Refinancing for Nasser Freres’ The Greyson in Jersey City

Walker & Dunlop Arranges $270 Million Refinancing for Nasser Freres’ The Greyson in Jersey City

BETHESDA, Md.–(BUSINESS WIRE)–Walker & Dunlop, Inc. announced today that it has arranged $270,000,000 in refinancing for The Greyson, a 28-story, 622-unit, Class A mixed-use residential tower developed by Nasser Freres in the heart of Jersey City’s Journal Square neighborhood. The financing marks a significant milestone for the development, supporting its transition from construction to stabilized operations and positioning the property for long-term success.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118022862/en/

The Greyson. Photo credits: Nasser Freres

The Greyson. Photo credits: Nasser Freres

Walker & Dunlop Capital Markets Institutional Advisory served as exclusive advisor to Nasser Freres, arranging a floating-rate, interest-only bridge loan from affiliates of Apollo. The transaction was arranged by Keith Kurland, Aaron Appel, Adam Schwartz, Jonathan Schwartz, Jordan Casella, Christopher de Raet, and Jack Krentzman.

“Journal Square has undergone a remarkable transformation, and The Greyson exemplifies the caliber of development attracting investment to the neighborhood,” said Kurland, senior managing director of Capital Markets and co-head of Institutional Advisory at Walker & Dunlop. “With its exceptional location, extensive amenities, and proximity to Manhattan, the property is well-positioned to capitalize on the area’s continued growth. We’re pleased to have worked with Nasser Freres and Apollo to execute this transaction.”

Located at 25 Cottage Street, The Greyson encompasses 424,328 rentable square feet, including 389,328 square feet of residential and 35,000 square feet of commercial space. The property features a collection of studio, one-, two-, and three-bedroom residences with unobstructed views of the Jersey City skyline. Designed to deliver an elevated residential experience, The Greyson offers an extensive suite of amenities, including an art gallery, children’s playroom, screening room, gaming lounge, virtual reality and sports room, coffee bar, fitness center, speakeasy, and private event space. Ground-floor retail space leased to a wine bar further enhances the property’s appeal while contributing to Journal Square’s growing dining and entertainment scene.

“From the outset, our vision for The Greyson was to create something truly distinctive, a property that would help shape the next chapter of residential living in Journal Square while contributing meaningfully to the neighborhood’s continued transformation,” said Michael Sokoloff, partner at Nasser Freres. “We’ve been intentional about every aspect of this development, from its architecture and design to the amenities and experiences we’re bringing to residents. We’re incredibly proud of what we’ve built and believe The Greyson will set a new standard for the neighborhood for years to come. This refinancing marks an exciting next chapter as we shift our focus to the property’s long-term success and we appreciate Walker & Dunlop’s advisory.”

Situated along the newly opened Homestead commercial corridor, the property is less than a five-minute walk from the Journal Square Transportation Center, offering direct PATH access to Lower and Midtown Manhattan in approximately 10 and 20 minutes, respectively. Journal Square has emerged as one of the New York metropolitan area’s fastest-growing rental submarkets, driven by demand for transit-oriented housing and rental rates that remain comparatively affordable to those along the Jersey City Waterfront and in Manhattan.

In the first half of 2026, Walker & Dunlop’s Capital Markets team sourced over $13.9 billion from non-Agency capital providers, including nearly $9.6 billion for multifamily properties. This vast experience has made them a top advisor on all asset classes for many of the industry’s top developers, owners, and operators. To learn more about Walker & Dunlop’s broad financing options, visit our website.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States and internationally. Our ideas and capital create communities where people live, work, shop, and play. Our innovative people, breadth of our brand, and our technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.

Media:

Nina H. von Waldegg

Public Relations

Phone 301.564.3291

[email protected]

Phone 301.215.5500

7272 Wisconsin Avenue, Suite 1300

Bethesda, Maryland 20814

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Finance Public Relations/Investor Relations Communications Professional Services Other Construction & Property Residential Building & Real Estate

MEDIA:

Photo
Photo
The Greyson. Photo credits: Nasser Freres
Logo
Logo

Everforth, Inc. Announces Withdrawal of Proposed Senior Notes Offering

Everforth, Inc. Announces Withdrawal of Proposed Senior Notes Offering

RICHMOND, Va.–(BUSINESS WIRE)–
Everforth, Inc. (NYSE: EFOR) (“Everforth”) announced today that it has withdrawn its previously proposed offering of $500 million in aggregate principal amount of senior notes due 2031 as a result of market conditions.

The proposed transaction was opportunistic to refinance the Company’s existing 4.625% senior notes well in advance of their May 2028 maturity. While Everforth had meaningful investor interest, the Company made the strategic decision to withdraw the offering as the terms do not reflect the strength of its business.

Everforth’s strong free cash flow and liquidity position provide the Company with significant financial flexibility. Everforth remains committed to using its free cash flow to reduce debt and further strengthen the balance sheet. The Company will continue to evaluate a range of financing alternatives to address the 2028 maturity.

This press release is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy any securities.

Safe Harbor

Certain statements made in this news release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and involve a high degree of risk and uncertainty. Forward-looking statements include statements regarding our anticipated financial and operating performance. All statements in this news release, other than those setting forth strictly historical information, are forward-looking statements. Forward-looking statements are not guarantees of future performance and actual results might differ materially. For a full list of risks and discussion of forward-looking statements, please see our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on February 25, 2026. We specifically disclaim any intention or duty to update any forward-looking statements contained in this news release.

Kimberly Esterkin

Vice President, Investor Relations

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Artificial Intelligence Internet

MEDIA:

Logo
Logo

BlackRock Health Sciences Term Trust (BMEZ) Announces Expiration and Preliminary Results of Tender Offer

BlackRock Health Sciences Term Trust (BMEZ) Announces Expiration and Preliminary Results of Tender Offer

NEW YORK–(BUSINESS WIRE)–
BlackRock Health Sciences Term Trust (the “Fund”) announced today the expiration and preliminary results of its tender offer (“Tender Offer”) for up to 5% of its outstanding common shares (the “Shares”).

The Tender Offer commenced on October 16, 2026 and expired at 5:00 p.m. Eastern time on November 18, 2026.

Based on preliminary information, the number of Shares properly tendered and not withdrawn is noted in the table below.

Fund Name

Ticker

CUSIP

Shares Offered

for Repurchase

Shares Tendered

(Preliminary Results)

BlackRock Health Sciences

Term Trust

BMEZ

09260E105

3,125,070

13,178,845

Based on the preliminary results shown above, because the Tender Offer was oversubscribed for the Fund, the relative number of Shares that will be purchased from each shareholder is expected to be prorated based on the number of Shares properly tendered for the Fund. The purchase price of properly tendered and accepted Shares for the Fund will be 98% of the Fund’s net asset value (“NAV”) as of the close of regular trading on the New York Stock Exchange on November 19, 2026, the business day immediately following the expiration date of the Tender Offer. The above-indicated results are based on preliminary information, are subject to adjustment and should not be regarded as final. The Fund expects to announce the final results of its Tender Offer, including the pro-ration factor, if applicable, on or about November 19, 2026.

Questions regarding the Tender Offer may be directed to Georgeson LLC, the Information Agent for the Tender Offer, toll free at (866) 961-4074.

IMPORTANT NOTICE

This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Fund. The offer to purchase the Fund’s common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission (“SEC”) as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Fund.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

Availability of Fund Updates

BlackRock will update performance and certain other data for the Funds on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Funds. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Funds and does not, and is not intended to, incorporate BlackRock’s website in this release.

Forward-Looking Statements

This press release, and other statements that BlackRock or a Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to a Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

With respect to the Funds, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Funds or in a Fund’s net asset value; (2) the relative and absolute investment performance of a Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to a Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.

Annual and Semi-Annual Reports and other regulatory filings of the Funds with the SEC are accessible on the SEC’s website at www.sec.govand on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Funds. The information contained on BlackRock’s website is not a part of this press release.

1-800-882-0052

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

  • Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month
    disease-free survival (DFS) of 81.1% in patients with resectable soft tissue sarcoma.
  • Patients with post-treatment tumour-infiltrating lymphocyte (TIL) levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels.
  • Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels.
  • Results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy.


SYDNEY, AUSTRALIA, Nov. 19, 2026 (GLOBE NEWSWIRE) —

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announced new data from the investigator-initiated EFTISARC-NEO Phase II study presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting (Poster number P 448).

The study is evaluating Immutep’s eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma. Forty patients were enrolled, and 38 patients underwent surgery and were included in the survival evaluation.

The latest analysis currently shows a disease-free survival (DFS) of 81.1% at 12 months. The current Kaplan-Meier estimate at 18 months is also 81.1%, although this later time point remains immature, and follow-up is ongoing. Among the 38 patients who underwent surgery and were evaluated, eight patients had experienced disease recurrence at the data cut-off (April 30, 2026).

Table 1 – Survival results for soft tissue sarcoma patients from EFTISARC-NEO

Outcome Latest Analysis
12-month disease-free survival (mature) 81.1%
18-month disease-free survival (immature) 81.1%
12-month local recurrence-free survival 94.1%
12-month distant metastasis-free survival 86.2%
Median follow-up 19.1 months


In addition, exploratory analyses showed that higher levels of tumour-infiltrating lymphocytes (TILs) and greater hyalinisation and fibrosis after treatment may be associated with better DFS. In particular, patients with post-treatment TIL levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels. Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels of hyalinisation and fibrosis. The presence of tertiary lymphoid structures (TLS) and baseline expression of PD-L1, LAG-3 and TIGIT did not correlate with survival outcomes.

These survival and exploratory findings build on previously reported EFTISARC-NEO results in which the trial met its primary endpoint with a median tumour hyalinisation/fibrosis of 51.5% following neoadjuvant therapy with efti, pembrolizumab and radiotherapy. The new data are consistent with efti’s mechanism of action, in which activation of antigen-presenting cells drives a stronger anti-tumour T cell response, and suggest that a stronger immune response in the tumour may be associated with improved patient survival outcomes.

Pawel Sobczuk, MD PhD, one of the Principal Investigators of EFTISARC-NEO, said: “These results are highly encouraging for patients with high-risk soft tissue sarcoma, where recurrence remains a major concern despite surgery and radiotherapy. Disease-free survival of approximately 81% maintained through 12 months and on a preliminary basis also at 18 months is an important observation, and the association between a strong immune response in the tumour and better disease-free survival is particularly compelling. Together with the substantial pathological responses previously reported, the findings reinforce the potential of this novel neoadjuvant approach and provide a strong rationale for continued follow-up and further clinical evaluation.”

Marc Voigt, CEO of Immutep, said: “With the data to date, EFTISARC-NEO is delivering an increasingly coherent and encouraging picture. The marked difference in outcomes between patients with higher and lower post-treatment immune cell infiltration is especially notable and is consistent with efti’s potential to help generate a stronger anti-tumour immune response. We believe these results strengthen the rationale for further potential clinical development in this indication, where patients remain in need of more effective treatment options.”

The poster is available on the Posters & Publications page of Immutep’s website.

Next Steps

Immutep anticipates reporting additional data from EFTISARC-NEO in CY2027.

Subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources, the Company is preparing to advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma, targeting initiation in H2 CY2027.

About EFTISARC-NEO

EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy as neoadjuvant treatment for patients with resectable soft tissue sarcoma. The trial is led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a grant from the Polish Medical Research Agency, with Immutep supplying efti.

The primary endpoint is pathological response, measured as the percentage of tumour hyalinisation/fibrosis at resection. Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response and health-related quality of life. Forty patients were enrolled, with enrolment completed in January 2025 (ClinicalTrials.gov: NCT06128863).

About Eftilagimod Alfa (efti)

Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer

This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; [email protected]

US Investors/Media:

Matthew Beck, astr partners
+1 (917) 415-1750; [email protected]



JOYY Reports Third Quarter 2026 Unaudited Financial Results

SINGAPORE, Nov. 19, 2026 (GLOBE NEWSWIRE) — JOYY Inc. (NASDAQ: JOYY) (“JOYY” or the “Company”), a global technology company, today announced its unaudited financial results for the third quarter of 2026.

Third Quarter 2026 Financial Highlights

1

  • Net revenues were US$624.6 million, an increase of 15.6% from US$540.2 million in the corresponding period of 2025, and an increase of 5.7% from US$590.8 million in the second quarter of 2026.

    • Social Entertainment net revenues increased by 8.8% to US$441.0 million from US$405.5 million in the corresponding period of 2025, and by 4.3% from US$422.7 million in the second quarter of 2026.
    • BIGO Adsnet revenues increased by 39.6% to US$145.7 million from US$104.4 million in the corresponding period of 2025, and by 9.0% from US$133.7 million in the second quarter of 2026.
    • Shopline net revenues increased by 24.7% to US$37.8 million from US$30.3 million in the corresponding period of 2025, and by 10.0% from US$34.4 million in the second quarter of 2026.
  • Operating income was US$13.5 million, compared with US$19.6 million in the corresponding period of 2025 and US$13.8 million in the second quarter of 2026.
  • Non-GAAP EBITDA

    2
    was US$55.7 million, an increase of 10.1% from US$50.6 million in the corresponding period of 2025, and compared with US$56.9 million in the second quarter of 2026.
  • Net income from continuing operations attributable to controlling interest of JOYY

    3
    was US$59.6 million, compared with US$62.0 million in the corresponding period of 2025 and US$51.8 million in the second quarter of 2026.
  • Non-GAAP net income from continuing operations attributable to controlling interest and common shareholders of JOYY

    4
    was US$67.1 million, compared with US$72.4 million in the corresponding period of 2025 and US$63.5 million in the second quarter of 2026.
  • Net Cash

    5
    as of September 30, 2026 was US$2,940.5 million.
  • Net Cash from operating activities was US$102.2 million, compared with US$73.4 million in the corresponding period of 2025.

Third Quarter 2026 Business Highlights

Global community:

  • Global average mobile MAUs

    6
    reached 278.8 million in the third quarter of 2026, up by 4.7% from 266.2 million in the corresponding period of 2025, and up by 0.6% from 277.1 million in the second quarter of 2026. The Company continued to optimize its marketing strategies to focus on return on investment (ROI) and high-value users.

Social Entertainment:

  • In the third quarter, Social Entertainment revenues increased by 8.8% year over year to US$441.0 million, with live streaming revenues reaching US$419.8 million, an 8.1% increase from the corresponding period of 2025. By region, live streaming revenues showed year-over-year growth across all four geographical areas.
  • In the third quarter, core live streaming paying users7 increased by 8.1% year over year to 1.64 million, while ARPPU8 was US$218.7.
  • Bigo Live continued to make enhancements across content operations, streamer ecosystem, and AI-driven capabilities. In content operations, the Company refined its cross-regional content algorithms, expanded live translation coverage and noise-resilient speech recognition, enabling users to discover diverse content and interact with streamers across regions. Improved onboarding and guidance for newly signed streamers contributed to a 4.7-percentage-point sequential increase in the share of newly signed streamers completing their first livestream. The Company also continued to expand AI-generated interactive content and virtual gifts. In September 2026, AI-generated interactive virtual gifts accounted for 35.4% of total virtual gift consumption on Bigo Live.

B2B Initiatives: Advertising Technology and Smart Commerce

  • Beginning in 2022, the Company ramped up efforts to diversify its revenue streams, cultivating its new initiatives in advertising technology and smart commerce. The Company has made steady progress advancing towards its strategic positioning as a global tech company powered by multiple growth engines. In the third quarter, total non-live streaming revenues reached US$204.7 million, up by 34.9% year over year, representing 32.8% of total net revenues of the Company, compared with 28.1% in the corresponding period of 2025.


BIGO Ads:

  • BIGO Ads is a global AI-powered programmatic advertising platform. Launched to provide one-stop marketing and monetization solutions, it leverages deep learning, real-time bidding, and smart bidding models to enable brands to scale user acquisition and app developers to effectively unlock monetization potential through connecting premium global demand.
  • In the third quarter, BIGO Ads’ total revenues grew by 39.6% year over year to US$145.7 million. In particular, BIGO Audience Network, which includes third-party advertising revenues generated on network partners’ traffic properties, maintained robust growth, with revenues increasing by 52.3% year over year.
  • BIGO Ads has access to a vast traffic pool, comprising the Company’s own global average mobile MAU base and an extensive network of third-party traffic through seamless integration of developer traffic across major channels. During the third quarter, Software Development Kit (SDK) traffic scale continued to expand, increasing by 55.6% year over year.
  • Broader traffic coverage, multi-vertical advertiser expansion, and ongoing algorithm optimization continued to fuel growth. Web-based demand grew approximately 328% year over year and 30% quarter over quarter, alongside solid performance from in-app demand.
  • BIGO Ads continued to invest in its algorithm and engineering infrastructure during the quarter. As its cross-channel attribution systems improved and advertiser conversion data accumulated, BIGO Ads broadened its data inputs for model training, improving predictions of conversion probability and user lifetime value. The platform also upgraded its model architecture to support different conversion objectives and traffic types, while refining its bidding algorithm to better assess the value of each ad impression and allocate advertiser budgets more effectively.


Shopline:

  • Shopline serves as a global AI-powered operating system for modern retail. Beyond storefront creation, Shopline offers a deeply integrated suite of merchant services across payments, logistics, marketing, and data analytics. It is an open, extensible omnichannel platform that enables merchants to manage the full commerce value chain from store setup and transactions to fulfillment, customer acquisition, and lifecycle engagement. Shopline has helped merchants in diverse industries across multiple markets to launch and scale their businesses.
  • Shopline currently generates revenues from recurring software subscription fees and a suite of transaction-based value-added services, including localized payment processing (Shopline Payments) and marketing solutions.
  • In the third quarter, Shopline generated revenues of US$37.8 million, up 24.7% year over year and 10.0% quarter over quarter. Notably, cross-border merchants revenue increased by 77.8% year over year. The Company continued to enhance Shopline Payments with more local payment options, stronger multi-currency payment support, and improved transaction management, helping merchants manage cross-border payments more easily and efficiently.
  • As AI platforms and agents emerge as new channels for product discovery and purchasing, Shopline continued to strengthen its AI Commerce capabilities. On the ecosystem front, Shopline expanded its integrations with leading AI platforms and AI agents, and enhanced its AI tools and interfaces for developers. On the merchant operations front, the Company rolled out its AI-powered commerce assistant, Shopline Omi, spanning product management, customer segmentation, promotional events, multilingual support, and detailed store performance analysis.

Ms. Ting Li, Chairperson and Chief Executive Officer of JOYY, commented, “This quarter, we made further progress toward becoming a global technology company powered by multiple growth engines. Total net revenues reached US$624.6 million, up 15.6% year over year and 5.7% quarter over quarter. Our Social Entertainment business remained on a steady course, while BIGO Ads and Shopline sustained robust performances, driving solid topline expansion and strong operating cash flow generation. We remain steadfast in our commitment to shareholder returns, having returned a total of US$536.0 million year-to-date through November 13, 2026, comprising US$216.2 million in dividends and US$319.8 million in share repurchases.

Social Entertainment revenues grew 8.8% year over year to US$441.0 million, supported by continued enhancements to Bigo Live’s content operations, streamer ecosystem, and AI-driven capabilities. Live streaming revenues and core live streaming paying users both increased 8.1% year over year. BIGO Ads revenues rose 39.6% year over year to US$145.7 million, led by 52.3% year-over-year growth in BIGO Audience Network as we expanded our traffic network, diversified advertiser demand, and improved our algorithms and ad delivery. Shopline revenues reached US$37.8 million, up 24.7% year over year, supported by continued expansion among cross-border merchants and strong momentum in Shopline Payments. We also advanced our AI Commerce initiatives to help merchants reach customers through emerging AI-powered shopping channels and strengthen Shopline’s role as an omnichannel e-commerce infrastructure platform.

Looking ahead to 2027, we believe JOYY will enter a pivotal phase in which our established strategy translates into stronger operating results. With clearer strategic trajectories across our three businesses, we are well positioned to deliver diversified and sustainable growth while creating long-term shareholder value.”

Third Quarter 2026 Financial Results


NET REVENUES

Net revenues were US$624.6 million, representing an increase of 15.6% from US$540.2 million in the corresponding period of 2025, and an increase of 5.7% from US$590.8 million in the second quarter of 2026.

Social Entertainment net revenues increased by 8.8% to US$441.0 million from US$405.5 million in the corresponding period of 2025, and by 4.3% from US$422.7 million in the second quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily driven by higher live streaming revenues, as expanded content categories and enhanced localized operations contributed to stronger user engagement and paying conversion across key markets.

BIGO Ads net revenues increased by 39.6% to US$145.7 million from US$104.4 million in the corresponding period of 2025, and by 9.0% from US$133.7 million in the second quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily driven by expansion of traffic, elevated advertiser demand across regions and verticals, and enhanced algorithm performance that resulted in improved advertisement delivery efficiency and higher advertiser spending.

Shopline net revenues increased by 24.7% to US$37.8 million from US$30.3 million in the corresponding period of 2025, and by 10.0% from US$34.4 million in the second quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily driven by continued merchant adoption and deeper penetration of value-added services.


COST OF REVENUES AND GROSS PROFIT

Cost of revenues was US$407.4 million in the third quarter of 2026, compared with US$347.1 million in the corresponding period of 2025 and US$389.2 million in the second quarter of 2026.

Social Entertainment’s cost of revenues increased by 7.4% year over year to US$274.3 million, and by 3.7% from US$264.6 million in the second quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily attributable to higher revenue-sharing fees and content costs of US$28.4 million and US$7.9 million, respectively.

BIGO Ads’ cost of revenues increased by 47.9% year over year to US$112.2 million, and by 5.6% from US$106.3 million in the second quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily attributable to higher traffic acquisition costs paid to third-party partners in relation to the expansion of BIGO Audience Network.

Shopline’s cost of revenues increased by 30.8% year over year to US$20.9 million, and by 13.9% from US$18.3 million in the second quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily attributable to higher payment processing costs, reflecting an increased contribution from payment services to Shopline’s revenue mix.

Gross profit was US$217.2 million in the third quarter of 2026, compared with US$193.1 million in the corresponding period of 2025 and US$201.6 million in the second quarter of 2026. Gross margin was 34.8% in the third quarter of 2026, compared with 35.8% in the corresponding period of 2025 and 34.1% in the second quarter of 2026.


OPERATING EXPENSES AND INCOME

Operating expenses were US$204.1 million in the third quarter of 2026, compared with US$174.2 million in the same period of 2025 and US$188.2 million in the second quarter of 2026. Among the operating expenses, sales and marketing expenses were US$86.7 million, compared with US$72.1 million in the corresponding period of 2025 and US$79.6 million in the second quarter of 2026. Research and development expenses were US$59.0 million, compared with US$63.1 million in the corresponding period of 2025 and US$53.0 million in the second quarter of 2026. General and administrative expenses were US$58.4 million, compared with US$39.1 million in the corresponding period of 2025 and US$55.6 million in the second quarter of 2026.

Operating income was US$13.5 million, compared with US$19.6 million in the corresponding period of 2025 and US$13.8 million in the second quarter of 2026.

Non-GAAP operating income9 was US$46.6 million in the third quarter of 2026, compared with US$40.7 million in the corresponding period of 2025 and US$49.1 million in the second quarter of 2026. Non-GAAP operating income margin10 was 7.5% in the third quarter of 2026, compared with 7.5% in the corresponding period of 2025 and 8.3% in the second quarter of 2026.

Non-GAAP EBITDA was US$55.7 million, compared with US$50.6 million in the corresponding period of 2025 and US$56.9 million in the second quarter of 2026. Non-GAAP EBITDA margin11 was 8.9%, compared with 9.4% in the corresponding period of 2025 and 9.6% in the second quarter of 2026.


NET INCOME

Net income from continuing operations attributable to controlling interest of JOYY was US$59.6 million, compared with US$62.0 million in the corresponding period of 2025 and US$51.8 million in the second quarter of 2026. Net income margin was 9.5% in the third quarter of 2026, compared with 11.5% in the corresponding period of 2025 and 8.8% in the second quarter of 2026.

Non-GAAP net income from continuing operations attributable to controlling interest and common shareholders of JOYY was US$67.1 million, compared with US$72.4 million in the corresponding period of 2025 and US$63.5 million in the second quarter of 2026. Non-GAAP net income margin12 was 10.7% in the third quarter of 2026, compared with 13.4% in the corresponding period of 2025 and 10.7% in the second quarter of 2026.


NET INCOME PER ADS

Diluted net income from continuing operations per ADS13 was US$1.20 in the third quarter of 2026, compared with US$1.15 in the corresponding period of 2025 and US$1.01 in the second quarter of 2026.

Non-GAAP diluted net income from continuing operations per ADS14 was US$1.36 in the third quarter of 2026, compared with US$1.36 in the corresponding period of 2025 and US$1.24 in the second quarter of 2026.


BALANCE SHEET AND CASH FLOWS

As of September 30, 2026, the Company had net cash of US$2,940.5 million, compared with US$3,258.0 million as of December 31, 2025. For the third quarter of 2026, net cash from operating activities was US$102.2 million.


SHARES OUTSTANDING

As of September 30, 2026, the Company had a total of 952.0 million common shares outstanding, representing the equivalent of 47.6 million ADSs assuming the conversion of all common shares into ADSs.

Business Outlook

For the fourth quarter of 2026, the Company expects net revenues to be between US$650 million and US$669 million. This forecast reflects the Company’s current and preliminary views on the market, operational conditions, and business strategies, which are subject to change, particularly as to the potential impact from macroeconomic uncertainties.

Share Repurchase Programs

Pursuant to the Company’s up-to-US$600 million share repurchase program authorized in May 2026, or the 2026 Share Repurchase Program, which is effective through the end of 2028, the Company had repurchased approximately 1.6 million ADSs for an aggregate consideration of US$120.5 million on the open market during the third quarter of 2026.

Between October 1, 2026 and November 13, 2026, the Company repurchased an additional approximately 0.5 million ADSs, for an aggregate consideration of US$38.4 million under the 2026 Share Repurchase Program. The remaining unutilized amount under the 2026 Share Repurchase Program was approximately US$368.2 million as of November 13, 2026.

Quarterly Dividend Program

On May 22, 2026, the board of directors of the Company authorized a quarterly dividend program, or the 2026 Dividend Program, under which a total of approximately US$900 million in cash will be distributed on a quarterly basis between 2026 and 2028.

Pursuant to the 2026 Dividend Program, the board of directors has accordingly declared a dividend of US$1.59 per ADS, or US$0.0795 per common share, for the third quarter of 2026, which is expected to be paid on January 15, 2027 to shareholders of record as of the close of business on December 30, 2026. The ex-dividend date will be December 30, 2026.

Conference Call Information

The Company will hold a conference call at 9:00 PM U.S. Eastern Time on Wednesday, November 18, 2026 (10:00 AM Singapore/Hong Kong Time on Thursday, November 19, 2026). Details for the conference call are as follows:

Event Title: JOYY Inc. Third Quarter 2026 Earnings Conference Call
Conference ID: #10058264


All participants may use the link provided below to complete the online registration process in advance of the conference call. Upon registration, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique PIN by email.

PRE-REGISTER LINK: https://s1.c-conf.com/diamondpass/10058264-x8r228.html

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.joyy.com.

The replay will be accessible through November 26, 2026, by dialing the following numbers:

United States: 1-855-883-1031
Singapore:
Hong Kong:
800-101-3223
800-930-639
Conference ID: #10058264



About JOYY Inc.

JOYY (NASDAQ: JOYY) is a leading global technology company, dedicated to building a self-reinforcing ecosystem that integrates social entertainment, programmatic advertising, and omnichannel e-commerce infrastructure, powered by AI and data intelligence. Headquartered in Singapore and operating across the globe, JOYY empowers creators, merchants and enterprises worldwide. JOYY’s ADSs have been listed on the NASDAQ since November 2012.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this press release, as well as JOYY’s strategic and operational plans, contain forward-looking statements. JOYY may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about JOYY’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: JOYY’s goals and strategies; JOYY’s future business development, results of operations and financial condition; the expected growth of the global online social entertainment, advertising and smart commerce market; JOYY’s ability to attract and retain users and customers; JOYY’s expectations regarding demand for and market acceptances of its products and services; JOYY’s ability to adopt the latest technology to enhance its operations; fluctuations in global economic and business conditions; and assumptions underlying or related to any of the foregoing. A more detailed and full discussion of those risks and other potential risks is included in JOYY’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and JOYY does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Use of Non-GAAP Financial Measures

The unaudited condensed consolidated financial information is prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). JOYY uses non-GAAP operating (loss) income, non-GAAP operating income (loss) margin, non-GAAP EBITDA, non-GAAP EBITDA margin, non-GAAP net income (loss) from continuing operations attributable to controlling interest and common shareholders of JOYY, non-GAAP net income (loss) margin attributable to controlling interest and common shareholders of JOYY, and basic and diluted non-GAAP net income (loss) from continuing operations per ADS, all of which are non-GAAP financial measures adjusted from the most comparable U.S. GAAP results. Non-GAAP operating income (loss) is operating income (loss) excluding share-based compensation expenses, impairment of goodwill and investments, amortization of intangible assets from business acquisitions, and gain (loss) on deconsolidation and disposal of subsidiaries and business. Non-GAAP operating income (loss) margin is non-GAAP operating income as a percentage of net revenues. Non-GAAP net income (loss) from continuing operations is net income (loss) from continuing operations excluding share-based compensation expenses, impairment of goodwill and investments, amortization of intangible assets from business acquisitions, gain (loss) on deconsolidation and disposal of subsidiaries and business, gain (loss) on disposal and deemed disposal of investments, gain (loss) on fair value change of investments, reconciling items on the share of equity method investments (referring to share of income (loss) from equity method investments resulting from non-recurring or non-cash items of the equity method investments), interest expenses related to the convertible bonds’ amortization to face value, and income tax effects of the above non-GAAP reconciling items. Non-GAAP EBITDA is non-GAAP operating income (loss) added back depreciation and amortization (other than amortization of intangible assets resulting from assets and business acquisitions), and non-GAAP EBITDA margin is non-GAAP EBITDA as a percentage of net revenues. Non-GAAP net income (loss) from continuing operations attributable to controlling interest and common shareholders of JOYY is net income (loss) from continuing operations attributable to controlling interest of JOYY excluding share-based compensation expenses, impairment of goodwill and investments, amortization of intangible assets from business acquisitions, gain (loss) on deconsolidation and disposal of subsidiaries and business, gain (loss) on disposal and deemed disposal of investments, gain (loss) on fair value change of investments, reconciling items on the share of equity method investments, interest expenses related to the convertible bonds’ amortization to face value, income tax effects of the above non-GAAP reconciling items and adjustments for non-GAAP reconciling items for the net income (loss) from continuing operations attributable to non-controlling interest shareholders. Non-GAAP net income (loss) margin is non-GAAP net income (loss) from continuing operations attributable to controlling interest and common shareholders of JOYY as a percentage of net revenues. Non-GAAP net income (loss) from continuing operations attributable to controlling interest and common shareholders of JOYY is net income (loss) from continuing operations attributable to common shareholders of JOYY excluding share-based compensation expenses, impairment of goodwill and investments, amortization of intangible assets from business acquisitions, gain (loss) on deconsolidation and disposal of subsidiaries and business, gain (loss) on disposal and deemed disposal of investments, gain (loss) on fair value change of investments, reconciling items on the share of equity method investments, interest expenses related to the convertible bonds’ amortization to face value, accretion, cumulative dividend and deemed dividend to subsidiaries’ preferred shareholders, gain on repurchase of redeemable convertible preferred shares of a subsidiary and income tax effects of above non-GAAP reconciling items and adjustments for non-GAAP reconciling items for the net income (loss) from continuing operations attributable to non-controlling interest shareholders. Basic and diluted non-GAAP net income (loss) from continuing operations per ADS is non-GAAP net income (loss) from continuing operations attributable to common shareholders of JOYY divided by weighted average number of ADS used in the calculation of basic and diluted net income (loss) per ADS. The Company believes that separate analysis and exclusion of the non-cash impact of above reconciling items adds clarity to the constituent parts of its performance. The Company reviews these non-GAAP financial measures together with GAAP financial measures to obtain a better understanding of its operating performance. It uses the non-GAAP financial measures for planning, forecasting and measuring results against the forecast. The Company believes that non-GAAP financial measures is useful supplemental information for investors and analysts to assess its operating performance without the non-cash effect of (i) share-based compensation expenses, amortization of intangible assets from business acquisitions, and interest expenses related to the convertible bonds’ amortization to face value, which have been and will continue to be significant recurring expenses in its business, (ii) impairment of goodwill and investments, gain (loss) on deconsolidation and disposal of subsidiaries and business, gain (loss) on disposal and deemed disposal of investments, gain (loss) on fair value change of investments, reconciling items on the share of equity method investments, accretion, cumulative dividend and deemed dividend to subsidiaries’ preferred shareholders and gain on repurchase of redeemable convertible preferred shares of a subsidiary which may not be recurring in its business, and (iii) income tax expenses and non-GAAP adjustments for net income (loss) from continuing operations attributable to non-controlling interest shareholders, which are affected by the above non-GAAP reconciling items. However, the use of non-GAAP financial measures has material limitations as an analytical tool. One of the limitations of using non-GAAP financial measures is that they do not include all items that impact the Company’s net income (loss) for the period. In addition, because non-GAAP financial measures are not measured in the same manner by all companies, they may not be comparable to other similar titled measures used by other companies. In light of the foregoing limitations, you should not consider non-GAAP financial measures in isolation from or as an alternative to the financial measures prepared in accordance with U.S. GAAP.

The presentation of these non-GAAP financial measures is not intended to be considered in isolation from, or as a substitute for, the financial information prepared and presented in accordance with U.S. GAAP. For more information on these non-GAAP financial measures, please see the table captioned “JOYY Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this press release.

Investor Relations Contact

JOYY Inc.

Investor Relations

Email: [email protected]

1 The financial information and non-GAAP financial information disclosed in this press release is presented on a continuing operations basis, unless otherwise specifically stated. Starting from the first quarter of 2026, the Company reports three segments, Social Entertainment, BIGO Ads and Shopline, to reflect changes made to the reporting structure whose financial information is reviewed by the chief operating decision makers of the Company under its evolving operating strategies. Social Entertainment mainly includes live streaming services on our social entertainment platforms including but not limited to Bigo Live, Likee, imo, and others. BIGO Ads mainly engages in advertising services on the Company’s own properties (specifically Likee and imo) and third-party network partners’ properties. Shopline mainly engages in providing omnichannel smart commerce solutions for merchants. Prior period segment information has been recast to conform to the current period’s presentation.

2 Non-GAAP EBITDA is a non-GAAP financial measure, which is defined as non-GAAP operating income (loss) added back depreciation and amortization (other than amortization of intangible assets resulting from assets and business acquisitions). Please refer to the section titled “Use of Non-GAAP Financial Measures” and the table captioned “JOYY Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this press release for details.

3 Net income (loss) from continuing operations attributable to controlling interest of JOYY is net income (loss) from continuing operations less net (loss) income from continuing operations attributable to the non-controlling interest shareholders and the mezzanine equity classified non-controlling interest shareholders.

4 Non-GAAP net income (loss) from continuing operations attributable to controlling interest and common shareholders of JOYY is a non-GAAP financial measure, which is defined as net income (loss) from continuing operations attributable to common shareholders of JOYY excluding share-based compensation expenses, impairment of goodwill and investments, amortization of intangible assets from business acquisitions, gain (loss) on deconsolidation and disposal of subsidiaries and business, gain (loss) on disposal and deemed disposal of investments, gain (loss) on fair value change of investments, reconciling items on the share of equity method investments which refer to those similar non-GAAP reconciling items of the Company, interest expenses related to the convertible bonds amortization to face value, accretion, cumulative dividend and deemed dividend to subsidiaries’ preferred shareholders, income tax effects of the above non-GAAP reconciling items and adjustments for non-GAAP reconciling items for net (loss) income attributable to non-controlling interest shareholders. Please refer to the section titled “Use of Non-GAAP Financial Measures” and the table captioned “JOYY Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this press release for details.

5 Net cash is calculated as the sum of cash and cash equivalents, restricted cash and cash equivalents, short-term deposits, restricted short-term deposits, short-term investments, long-term deposits and held-to-maturity investments and restricted held-to-maturity investments, less short-term and long-term loans.

6 Refers to average mobile monthly active users of the social entertainment platforms operated by the Company, including Bigo Live, Likee, imo and Hago. Average mobile MAU for any period is calculated by dividing (i) the sum of the Company’s active mobile users for each month of such period, by (ii) the number of months in such period.

7 Core live streaming paying users during a given period is calculated as the cumulative number of registered user accounts that have purchased virtual items or other products and services on Bigo Live, Likee or imo at least once during the relevant period.

8
 Average revenue per user is calculated by dividing the Company’s total revenues from live streaming on Bigo Live, Likee and imo during a given period by the number of paying users for the Company’s live streaming services on these platforms for that period.

9 Non-GAAP operating income (loss) is a non-GAAP financial measure, which is defined as operating income (loss) excluding share-based compensation expenses, amortization of intangible assets from business acquisitions, impairment of goodwill and investments and gain (loss) on deconsolidation and disposal of subsidiaries and business. Please refer to the section titled “Use of Non-GAAP Financial Measures” and the table captioned “JOYY Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this press release for details.

1
0 Non-GAAP operating income (loss) margin is a non-GAAP financial measure, which is defined as non-GAAP operating income (loss) as a percentage of net revenues. Please refer to the section titled “Use of Non-GAAP Financial Measures” and the table captioned “JOYY Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this press release for details.

1
1 Non-GAAP EBITDA margin is a non-GAAP financial measure, which is defined as non-GAAP EBITDA as a percentage of net revenues. Please refer to the section titled “Use of Non-GAAP Financial Measures” and the table captioned “JOYY Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this press release for details.

1
2 Non-GAAP net income (loss) margin is non-GAAP net income from continuing operations attributable to controlling interest and common shareholders of JOYY as a percentage of net revenues.

1
3 ADS refers to American Depositary Share. Each ADS represents twenty Class A common shares of the Company. Diluted net income (loss) per ADS is net income (loss) attributable to common shareholders of JOYY divided by weighted average number of diluted ADS.

1
4 Non-GAAP diluted net income (loss) from continuing operations per ADS is a non-GAAP financial measure, which is defined as non-GAAP net income (loss) from continuing operations attributable to common shareholders of JOYY divided by weighted average number of ADS used in the calculation of diluted net income (loss) per ADS. Please refer to the section titled “Use of Non-GAAP Financial Measures” and the table captioned “JOYY Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this press release for details.

JOYY INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(All amounts in thousands, except share, ADS and per ADS data)
 
      December 31,   September 30,
      2025   2026
      US$   US$
Assets        
Current assets        
  Cash and cash equivalents   374,248   455,552
  Restricted cash and cash equivalents   21,593   35,790
  Short-term deposits   192,535   166,332
  Restricted short-term deposits   7,182   15,850
  Short-term investments   613,702   901,509
  Accounts receivable, net   154,439   167,712
  Amounts due from related parties   106   365
  Prepayments and other current assets   255,566   330,509
           
Total current assets   1,619,371   2,073,619
           
Non-current assets        
  Long-term deposits and held-to-maturity investments   2,059,386   1,412,308
  Restricted held-to-maturity investments   –   20,000
  Deferred tax assets   9,782   9,754
  Investments   551,802   638,385
  Property and equipment, net   565,124   631,942
  Land use rights, net   301,390   307,909
  Intangible assets, net   221,963   180,745
  Right-of-use assets, net   21,241   22,902
  Goodwill   2,194,358   2,194,425
  Other non-current assets   8,071   7,023
           
Total non-current assets   5,933,117   5,425,393
           
Total assets   7,552,488   7,499,012
           
Liabilities, mezzanine equity and shareholders’ equity        
Current liabilities        
  Short-term loans   10,672   66,822
  Accounts payable   71,551   70,946
  Deferred revenue   61,713   60,692
  Advances from customers   5,408   10,034
  Income taxes payable   64,533   71,945
  Accrued liabilities and other current liabilities   626,678   669,604
  Amounts due to related parties   24,472   38,596
  Lease liabilities due within one year   8,939   8,669
           
Total current liabilities   873,966   997,308
           
Non-current liabilities        
  Lease liabilities   12,029   14,446
  Deferred revenue   9,522   8,832
  Deferred tax liabilities   54,941   68,114
  Other non-current liabilities   –   782
           
Total non-current liabilities   76,492   92,174
           
Total liabilities   950,458   1,089,482

JOYY INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
(All amounts in thousands, except share, ADS and per ADS data)
           
      December 31,   September 30,
      2025   2026
      US$   US$
           
Mezzanine equity   25,333     26,533  
           
Shareholders’ equity        
  Class A common shares (US$0.00001 par value; 10,000,000,000 and 10,000,000,000 shares authorized, 1,306,734,444 shares issued and 673,183,174 shares outstanding as of December 31, 2025; 1,153,846,924 shares issued and 625,508,212 shares outstanding as of September 30, 2026, respectively)   7     6  
  Class B common shares (US$0.00001 par value; 1,000,000,000 and 1,000,000,000 shares authorized, 326,509,555 and 326,509,555 shares issued and outstanding as of December 31, 2025 and September 30, 2026, respectively)   3     3  
  Treasury shares (US$0.00001 par value; 633,551,270 and 528,338,712 shares held as of December 31, 2025 and September 30, 2026, respectively)   (1,302,098 )   (1,194,344 )
  Additional paid-in capital   3,315,070     2,972,803  
  Statutory reserves   37,869     37,876  
  Retained earnings   4,699,089     4,643,913  
  Accumulated other comprehensive loss   (208,093 )   (103,241 )
           
Total JOYY Inc.’s shareholders’ equity   6,541,847     6,357,016  
           
Non-controlling interests   34,850     25,981  
           
Total shareholders’ equity   6,576,697     6,382,997  
           
Total liabilities, mezzanine equity and shareholders’ equity   7,552,488     7,499,012  

JOYY INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(All amounts in thousands, except share, ADS and per ADS data)
                     
    Three Months Ended   Nine Months Ended
    September 30,   June 30,   September 30,   September 30,   September 30,
    2025   2026   2026   2025   2026
    US$   US$   US$   US$   US$
Net revenues                    
Live streaming(1)   388,474     402,633     419,830     1,135,231     1,202,728  
Advertising   112,516     146,445     160,078     297,288     443,727  
Others   39,231     41,676     44,661     109,813     124,568  
                     
Total net revenues   540,221     590,754     624,569     1,542,332     1,771,023  
                     
Cost of revenues(2)   (347,090 )   (389,159 )   (407,356 )   (985,341 )   (1,162,918 )
                     
Gross profit   193,131     201,595     217,213     556,991     608,105  
                     
Operating expenses

(


2)
                   
Research and development expenses   (63,094 )   (53,024 )   (59,006 )   (185,595 )   (173,217 )
Sales and marketing expenses   (72,072 )   (79,587 )   (86,704 )   (216,055 )   (245,940 )
General and administrative expenses   (39,050 )   (55,632 )   (58,430 )   (119,662 )   (156,634 )
                     
Total operating expenses   (174,216 )   (188,243 )   (204,140 )   (521,312 )   (575,791 )
                     
Loss on deconsolidation and disposal of subsidiaries   –     –     –     –     (245 )
Other income   637     451     474     1,876     2,114  
                     
Operating income   19,552     13,803     13,547     37,555     34,183  
                     
Interest expenses   (97 )   (112 )   (223 )   (354 )   (373 )
Interest income and investment income   41,548     39,476     38,112     121,734     117,353  
Foreign currency exchange losses, net   (6,370 )   (13,502 )   (9,035 )   (5,940 )   (36,092 )
Loss on disposal and deemed disposal of investments   –     (415 )   (691 )   –     (1,106 )
Gain (loss) on fair value change of investments   4,102     1,461     4,656     22,440     (1,841 )
                     
Income before income tax expenses   58,735     40,711     46,366     175,435     112,124  
                     
Income tax expenses   (3,784 )   (9,849 )   (8,831 )   (15,061 )   (23,514 )
                     
Income before share of income (loss) in equity method investments, net of income taxes   54,951     30,862     37,535     160,374     88,610  
                     
Share of income (loss) in equity method investments, net of income taxes   4,236     17,887     19,649     (258 )   65,489  
                     
Net income from continuing operations   59,187     48,749     57,184     160,116     154,099  
                     
Gain on disposal of YY Live

(


3)
  –     –     –     1,875,921     –  
                     
Net income   59,187     48,749     57,184     2,036,037     154,099  
                     
Net loss attributable to the non-controlling interest shareholders and the mezzanine equity classified non-controlling interest shareholders   2,773     3,045     2,433     8,071     7,979  
                     
Net income attributable to controlling interest of JOYY Inc.   61,960     51,794     59,617     2,044,108     162,078  
                     
Including:                    
Net income from continuing operations attributable to controlling interest of JOYY Inc.   61,960     51,794     59,617     168,187     162,078  
Gain on disposal of YY Live

(


3)
  –     –     –     1,875,921     –  
                     
Accretion of subsidiaries’ redeemable convertible preferred shares to redemption value   (347 )   (346 )   (346 )   (1,041 )   (1,038 )
                     
Net income attributable to common shareholders of JOYY Inc.   61,613     51,448     59,271     2,043,067     161,040  
                     
Including:                    
Net income from continuing operations attributable to common shareholders of JOYY Inc.   61,613     51,448     59,271     167,146     161,040  
Gain on disposal of YY Live

(


3)
  –     –     –     1,875,921     –  

JOYY INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (CONTINUED)
(All amounts in thousands, except share, ADS and per ADS data)
                               
    Three Months Ended     Nine Months Ended  
    September 30,     June 30,     September 30,     September 30,     September 30,  
    2025     2026     2026     2025     2026  
    US$     US$     US$     US$     US$  
                               
Net income per ADS                              
——Basic   1.17     1.03     1.22     38.64     3.24  
Continuing operations   1.17     1.03     1.22     3.16     3.24  
Discontinued operations   –     –     –     35.48     –  
——Diluted   1.15     1.01     1.20     38.20     3.18  
Continuing operations   1.15     1.01     1.20     3.13     3.18  
Discontinued operations   –     –     –     35.07     –  
                               
Weighted average number of ADS used in calculating net income per ADS                              
——Basic   52,557,478     50,047,670     48,411,977     52,877,958     49,632,171  
——Diluted   53,354,913     51,121,698     49,353,188     53,484,775     50,564,470  
                               
                               
(1) Net revenues by geographical areas were as follows:
                               
    Three Months Ended     Nine Months Ended  
    September 30,     June 30,     September 30,     September 30,     September 30,  
    2025     2026     2026     2025     2026  
    US$     US$     US$     US$     US$  
                               
Developed countries and regions   325,027     361,763     377,331     893,787     1,082,338  
Middle East   57,404     63,168     68,358     185,323     190,286  
Mainland China   49,229     58,128     61,911     148,905     172,102  
Southeast Asia and others   108,561     107,695     116,969     314,317     326,297  
                               
Note: Developed countries and region mainly included the United States of America, Singapore, Japan, South Korea and Great Britain. Middle East mainly included Saudi Arabia and other countries located in the region. Southeast Asia and others mainly included Indonesia, Vietnam and rest of the world.
                               
(2) Share-based compensation was allocated in cost of revenues and operating expenses as follows:
                               
    Three Months Ended     Nine Months Ended  
    September 30,     June 30,     September 30,     September 30,     September 30,  
    2025     2026     2026     2025     2026  
    US$     US$     US$     US$     US$  
                               
Cost of revenues   1,416     964     1,214     2,728     2,980  
Research and development expenses   2,444     2,245     1,352     6,187     5,077  
Sales and marketing expenses   326     283     471     810     1,176  
General and administrative expenses   3,372     13,125     10,655     7,037     38,413  
                               
(3) Gain from disposal of YY Live amounted to approximately US$1.9 billion, which was reported as part of the net income from discontinued operations in the first quarter of 2025.

JOYY INC.
UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS
(All amounts in thousands, except share, ADS and per ADS data)
                     
    Three Months Ended   Nine Months Ended
    September 30,   June 30,   September 30,   September 30,   September 30,
    2025   2026   2026   2025   2026
    US$   US$   US$   US$   US$
                     
Operating income   19,552     13,803     13,547     37,555     34,183  
Share-based compensation expenses   7,558     16,617     13,692     16,762     47,646  
Amortization of intangible assets from business acquisitions   13,540     13,540     13,540     40,620     40,620  
Impairment of goodwill and investments   –     5,136     5,822     15,000     10,958  
Loss on deconsolidation and disposal of subsidiaries   –     –     –     –     245  
Non-GAAP operating income   40,650     49,096     46,601     109,937     133,652  
Depreciation and other amortization   9,905     7,802     9,052     29,198     24,635  
Non-GAAP EBITDA   50,555     56,898     55,653     139,135     158,287  
                     
Net income from continuing operations   59,187     48,749     57,184     160,116     154,099  
Share-based compensation expenses   7,558     16,617     13,692     16,762     47,646  
Amortization of intangible assets from business acquisitions   13,540     13,540     13,540     40,620     40,620  
Impairment of goodwill and investments   –     5,136     5,822     15,000     10,958  
Loss on deconsolidation and disposal of subsidiaries   –     –     –     –     245  
Loss on disposal and deemed disposal of investments   –     415     691     –     1,106  
(Gain) loss on fair value change of investments   (4,102 )   (1,461 )   (4,656 )   (22,440 )   1,841  
Income tax effects on non-GAAP adjustments   (1,930 )   (2,067 )   (1,548 )   (2,421 )   (6,627 )
Reconciling items on the share of equity method investments   (4,111 )   (19,525 )   (19,474 )   (1,190 )   (69,191 )
Non-GAAP net income from continuing operations   70,142     61,404     65,251     206,447     180,697  
                     
Net income from continuing operations attributable to common shareholders of JOYY Inc.   61,613     51,448     59,271     167,146     161,040  
Share-based compensation expenses   7,558     16,617     13,692     16,762     47,646  
Amortization of intangible assets from business acquisitions   13,540     13,540     13,540     40,620     40,620  
Impairment of goodwill and investments   –     5,136     5,822     15,000     10,958  
Loss on deconsolidation and disposal of subsidiaries   –     –     –     –     245  
Loss on disposal and deemed disposal of investments   –     415     691     –     1,106  
(Gain) loss on fair value change of investments   (4,102 )   (1,461 )   (4,656 )   (22,440 )   1,841  
Accretion, cumulative dividend and deemed dividend to subsidiaries’ preferred shareholders   347     346     346     1,041     1,038  
Income tax effects on non-GAAP adjustments   (1,930 )   (2,067 )   (1,548 )   (2,421 )   (6,627 )
Reconciling items on the share of equity method investments   (4,111 )   (19,525 )   (19,474 )   (1,190 )   (69,191 )
Non-GAAP adjustments for net loss attributable to the non-controlling interest shareholders   (492 )   (973 )   (625 )   (1,943 )   (2,200 )
Non-GAAP net income from continuing operations attributable to controlling interest and common shareholders of JOYY Inc.   72,423     63,476     67,059     212,575     186,476  
                     
                     
Non-GAAP net income from continuing operations per ADS                    
——Basic   1.38     1.27     1.39     4.02     3.76  
——Diluted   1.36     1.24     1.36     3.97     3.69  
                     
Weighted average number of ADS used in calculating Non-GAAP net income from continuing operations per ADS                    
——Basic   52,557,478     50,047,670     48,411,977     52,877,958     49,632,171  
——Diluted   53,354,913     51,121,698     49,353,188     53,484,775     50,564,470  

JOYY INC.
UNAUDITED SEGMENT REPORT
(All amounts in thousands, except share, ADS and per ADS data)
                     
    Three Months Ended   Nine Months Ended
    September 30,   June 30,   September 30,   September 30,   September 30,
    2025   2026   2026   2025   2026
    US$   US$   US$   US$   US$
Net revenues:                    
Social Entertainment   405,530     422,740     441,046     1,187,104     1,264,153  
BIGO Ads   104,382     133,653     145,730     271,888     404,170  
Shopline   30,309     34,361     37,793     83,340     102,700  
Total net revenues   540,221     590,754     624,569     1,542,332     1,771,023  
                     
Cost of revenues

(


1)

:
                   
Social Entertainment   (255,280 )   (264,559 )   (274,272 )   (751,249 )   (794,810 )
BIGO Ads   (75,839 )   (106,253 )   (112,191 )   (189,380 )   (314,044 )
Shopline   (15,971 )   (18,347 )   (20,893 )   (44,712 )   (54,064 )
Total cost of revenues   (347,090 )   (389,159 )   (407,356 )   (985,341 )   (1,162,918 )
                     
Gross profit:                    
Social Entertainment   150,250     158,181     166,774     435,855     469,343  
BIGO Ads   28,543     27,400     33,539     82,508     90,126  
Shopline   14,338     16,014     16,900     38,628     48,636  
Total gross profit   193,131     201,595     217,213     556,991     608,105  
                     
(1) Share-based compensation allocated to cost of revenues by segment as follows:
                     
    Three Months Ended   Nine Months Ended
    September 30,   June 30,   September 30,   September 30,   September 30,
    2025   2026   2026   2025   2026
    US$   US$   US$   US$   US$
                     
Social Entertainment   1,408     984     1,212     2,646     3,022  
BIGO Ads   20     33     26     22     75  
Shopline   (12 )   (53 )   (24 )   60     (117 )
Total share-based compensation allocated to cost of revenues   1,416     964     1,214     2,728     2,980  



Enerflex Ltd. Announces CFO Transition

CALGARY, Alberta, Nov. 18, 2026 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today announced the appointment of Christine Morris as Senior Vice President and Chief Financial Officer, effective January 1, 2027. Ms. Morris will succeed Preet S. Dhindsa, who will step down from his role effective December 31, 2026.

Paul Mahoney, Enerflex’s President and Chief Executive Officer, commented: “We thank Preet for his leadership and contributions to Enerflex over the past three years. During his tenure as CFO and period as interim CEO, Enerflex successfully completed the integration of Exterran, strengthened its financial flexibility, and established a solid foundation for continued growth and shareholder value creation.”

Mr. Mahoney continued, “We are pleased to welcome Christine to Enerflex at a critical point for the Company. As we progress towards the strategic objectives highlighted during our May investor update, our priorities remain clear. We are focused on capturing end market opportunities that can drive meaningful growth across the business, improving profitability, enhancing cash conversion, and driving higher returns on capital. Christine’s deep financial and leadership experience are highly complementary to our leadership team, and we look forward to her strong contributions as Enerflex drives value creation through growth and direct shareholder returns.”

About Christine Morris

Ms. Morris is a seasoned public company CFO and strategic advisor with a global track record of driving shareholder value. She has over 30 years of global financial leadership experience across the energy, industrial, and technology sectors, holding senior roles with major international organizations, including BT Group, Maersk Drilling, BJ Services, and Halliburton. Ms. Morris’ expertise spans financial strategy, operational performance, capital markets, mergers and acquisitions, and business transformation.

Ms. Morris holds a Master of Business Administration from Stanford University, a Master of Science in Actuarial Sciences, and a Bachelor of Science in Mathematical Sciences from the Catholic University of Louvain in Belgium.

ABOUT ENERFLEX

Enerflex is a leading provider of modular natural gas, power, and treated water technology solutions, delivering value through disciplined execution and a deliberate approach to where we compete. Our customer-focused delivery model supports operational excellence, innovation, and scalability across our global footprint with a focus on creating long-term shareholder value.

With approximately 4,500 engineers, manufacturers, technicians, professionals, and innovators, Enerflex is bound together by a shared vision: Transforming Energy for a Sustainable Future. The Company remains committed to the future of natural gas and the critical role it plays, while focused on sustainability offerings to support the world’s energy needs.

Enerflex’s common shares trade on the Toronto Stock Exchange under the symbol “EFX” and on the New York Stock Exchange under the symbol “EFXT”. For more information about Enerflex, visit www.enerflex.com.

For investor and media enquiries, contact:

Paul Mahoney
President and Chief Executive Officer
E-mail: [email protected]

Jeff Fetterly
Vice President, Corporate Development and Capital Markets
E-mail: [email protected]



HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

— A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition —

— Broad-spectrum activity across multiple KRAS mutations, combining inhibition of both ON and OFF states to intercept adaptive resistance —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces preclinical data for HMPL-A830 presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held on November 18–20, 2026, in Barcelona, Spain. HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate (“ATTC”) drug candidate comprises a highly selective and potent KRAS small molecule inhibitor payload conjugated to an anti‑epidermal growth factor receptor (“EGFR”) antibody.

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. While recent targeted therapies have validated KRAS (the most dominant RAS isoform) as a viable therapeutic target, significant clinical gaps remain, including safety limitations and disease progression driven by acquired resistance, often mediated by upstream receptor tyrosine kinase upregulation. HMPL-A830 is designed to address this unmet need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.

In vitro profiling demonstrated that its pan-KRAS payload exhibits a dual-action mechanism, simultaneously blocking both KRAS “ON” (GTP-RAF1 binding) and “OFF” (GDP-to-GTP exchange) activities. Potent antiproliferative activity was observed across a broad panel of 55 tumor cell lines harboring diverse KRAS alterations, including G12C, G12D, G12V and G13D mutations, as well as wild-type amplification. HMPL-A830 exhibited high binding affinity and rapid internalization into EGFR-positive cells. It also demonstrated a strong bystander killing effect, effectively eliminating neighboring EGFR-negative tumor cells, while maintaining robust antibody-dependent cellular cytotoxicity (ADCC) activity.

In mouse models, HMPL-A830 showed dose-dependent and robust antitumor efficacy across various EGFR-positive tumor models harboring KRAS alterations. HMPL-A830 achieved more durable tumor regressions than KRAS G12C inhibitors and outperformed several comparative regimens, including its unconjugated antibody, a pan-RAS inhibitor (administered alone or in combination with cetuximab), and a TROP2-targeted Topo I-inhibitor antibody-drug conjugate. Pharmacokinetic and pharmacodynamic (PK/PD) analyses confirmed a stronger and more sustained inhibition of EGFR/KRAS downstream signaling than the naked antibody, alongside a stable drug-to-antibody ratio (DAR) maintained in mouse, monkey, and human plasma.

In September 2026, HUTCHMED Limited (a subsidiary of the Company) entered into an exclusive development and license agreement with a subsidiary of GSK plc (“GSK”), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. HUTCHMED Limited is responsible for the global Phase I development program of HMPL-A830. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan. 

The Phase Ia part of an ongoing global Phase I trial is currently evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors (NCT07718581).

About HUTCHMED ATTCs

HUTCHMED’s ATTCs represent a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action. Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in both efficacy and safety.

Built on over 20 years of targeted therapy expertise, the ATTC platforms enable development of drug candidates across diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve accessibility to tumors and reduce off-tumor toxicity. This may overcome the on-target, off-tumor toxicity limitations of systemically-delivered small molecule inhibitors, which in turn could ensure safer long-term use and support combinations with chemotherapy and immunotherapy in earlier-line treatments.

About KRAS

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer (“CRC”), 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma (“PDAC”) patients.1 KRAS regulates key downstream pathways, including RAS/MAPK and PI3K/AKT/mTOR, to drive cell differentiation, proliferation, and survival.

While recent targeted therapies have validated KRAS as a viable therapeutic target, significant clinical gaps persist, particularly for patients with non-G12C mutations. Most patients eventually experience disease progression driven by acquired resistance, largely fueled by upstream receptor tyrosine kinase upregulation and secondary KRAS alterations. Beyond mutation coverage, systemic delivery of pan-KRAS and pan-RAS inhibitors is associated with on-target toxicities, such as dermatological toxicity reflecting RAS pathway inhibition in normal tissue. These present challenges for dosing, long-term tolerability, and combination with cytotoxic chemotherapy or immunotherapy backbones that constitute frontline standard-of-care.

About EGFR

EGFR is a widely expressed receptor tyrosine kinase and established driver of tumor cell proliferation, survival, and disease progression across multiple solid tumors, including CRC, PDAC, and non-small cell lung cancer (“NSCLC”). Signaling through EGFR activates the downstream RAS/MAPK and PI3K/AKT/mTOR pathways, positioning the receptor immediately upstream of KRAS. EGFR has also emerged as a key mediator of resistance to KRAS-targeted therapies, particularly in CRC, where adaptive feedback and increased upstream EGFR signaling reactivate the MAPK pathway and limit the depth and durability of KRAS inhibition. Together, these provide a strong rationale for the dual targeting of EGFR and KRAS, not only in CRC but also additional indications such as PDAC and NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including, without limitation, statements concerning HUTCHMED’s future plans and prospects, its expectations regarding the therapeutic potential of HMPL-A830 and other drug candidates from the ATTC platform and the further development of HMPL-A830 and other drug candidates from the ATTC platform in this and other indications, as well as the safety, efficacy, tolerability, scalability or combinability of all candidates from the ATTC platform. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the amount and timely receipt of the considerations; satisfaction of the conditions precedent to the consummation of the proposed transactions (including the ability of the parties to secure regulatory approvals on the terms expected, at all or in a timely manner); the ability of the parties to complete the proposed transactions; the continued sufficiency of preclinical and clinical data to support development and approval of the ATTC-based R&D candidates in China, the United States and other jurisdictions; their potential to gain clinical trial approvals from regulatory authorities; the efficacy and safety profile of HMPL-A830 and other drug candidates from the ATTC platform; the timing and outcome of clinical studies and the sufficiency of clinical data to support an new drug application submission of HMPL-A830 and other drug candidates from the ATTC platform in China, the United States or other jurisdictions; its potential to gain approvals from regulatory authorities on an expedited basis or at all; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or the regulatory pathway for the ATTC candidates; HUTCHMED or GSK’s ability to fund, implement and complete its further clinical development and commercialization plans for HMPL-A830 and other drug candidates from the ATTC platform and the timing of these events. In addition, when or if used herein, the words and phrases “aims,” “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “on track,” “predicts,” “plans,” “potential,” “promising,” “should,” “to be,” “will,” and similar expressions and their variants, as they relate to HUTCHMED may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although HUTCHMED believes the expectations reflected in such forward-looking statements are reasonable, HUTCHMED can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied HUTCHMED’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, assumptions regarding the safety, efficacy, supply, continued regulatory approval of these therapeutics, and in some cases connected to the risks of the use of other drug products as combination therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries +852 2121 8200 / [email protected]
   
Media Enquiries  
FTI Consulting – +44 20 3727 1030 / [email protected]
Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7779 436 689 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) / [email protected]
   
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
   
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
   
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000

_______________
REFERENCES
1  Singhal A, Li BT & O’Reilly EM. Targeting KRAS in cancer. Nat Med 30, 969–983 (2024). DOI: 10.1038/s41591-024-02903-0



TIME Names Bloom Energy Among America’s Top Manufacturers of 2027

TIME Names Bloom Energy Among America’s Top Manufacturers of 2027

SAN JOSE, Calif.–(BUSINESS WIRE)–Bloom Energy (NYSE: BE), a global leader in power solutions, today announced that it has been named to TIME’s list of America’s Top Manufacturers of 2027.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118727682/en/

America's Top Manufacturers of 2027

America’s Top Manufacturers of 2027

The list, developed by TIME and Statista, recognizes 250 U.S. manufacturers based on financial performance, innovation capacity and employment metrics. Companies were evaluated using measures including revenue growth, research and development investment, workforce growth and retention, and workplace safety.

“At Bloom, technology and manufacturing innovation go hand in hand,” said Satish Chitoori, Chief Operations Officer at Bloom Energy. “We have spent years building the people, processes and manufacturing capability required to take a highly complex energy technology and produce it at scale in the United States. That capability matters more than ever as demand for power is growing at a pace the traditional infrastructure model was not designed to meet. The digital era requires digital power solutions, and Bloom meets that need for a wide range of essential industries. This recognition belongs to the teams who make that possible every day.”

Bloom manufactures its fuel cell technology in the United States, with manufacturing operations in Fremont, California, and Newark, Delaware. The company’s platform provides clean, highly reliable power that can be rapidly deployed onsite, helping customers meet growing electricity requirements as power demand accelerates across data centers, commercial and industrial sectors, and other critical industries.

TIME’s recognition comes as U.S. manufacturing is increasingly important to the infrastructure required to support AI and data center growth. In announcing the 2027 list, TIME highlighted electrical equipment as the sector with the largest representation among America’s top manufacturers and pointed to surging demand associated with data center construction.

TIME and Statista considered thousands of companies with at least $100 million in 2025 revenue and U.S. production facilities. The analysis drew on company disclosures, public databases, patent analytics, Form 10-K filings, ESG and CSR reports, and Occupational Safety and Health Administration data.

The full TIME list and methodology are available here.

About Bloom Energy

Bloom Energy empowers enterprises to meet soaring energy demands and responsibly take charge of their power needs. The company’s fuel cell systems provide ultra-reliable, clean and highly scalable onsite electricity for Fortune 500 customers around the world, including data centers, semiconductor manufacturing, large utilities and other commercial and industrial sectors, as well as mission-critical organizations in local communities, such as hospitals, college campuses and retailers. Headquartered in Silicon Valley, Bloom Energy employs more than 2,000 people worldwide and manufactures its systems in the United States. For more information, visit BloomEnergy.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or the negative of these words or similar terms or expressions that concern Bloom’s expectations, strategy, priorities, plans or intentions. These forward-looking statements include, but are not limited to, the ability of Bloom to meet the digital power solution needs of the digital era for a wide range of industries. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, but not limited to, risks and uncertainties detailed in Bloom’s SEC filings. More information on potential risks and uncertainties that may impact Bloom’s business are set forth in Bloom’s periodic reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 9, 2026, its Quarterly Reports on Form 10-Q for the quarter ended March 31, 2026 and June 30, 2026, filed with the SEC on April 29, 2026 and July 28, 2026, respectively, as well as subsequent reports filed with or furnished to the SEC. Bloom assumes no obligation to, and does not intend to, update any such forward-looking statements.

Investor Relations
Michael Tierney
[email protected]

Media Relations
Katja Gagen
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Other Energy Environment Utilities Alternative Energy Green Technology Energy

MEDIA:

Photo
Photo
America’s Top Manufacturers of 2027
Logo
Logo

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals

Livsayis is Regeneron’s first approved siRNA therapy and neurology medicine

TARRYTOWN, N.Y., Nov. 18, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive, the predominant form of the disease. Livsayis is a novel, complement component factor 5 (C5)-directed small interfering RNA (siRNA) therapeutic that reduces levels of circulating C5 protein, limiting terminal complement activation, a key driver of the disease. It is the first and only approved siRNA therapy in gMG and the only FDA-approved gMG treatment administered subcutaneously four times a year.

“For people living with gMG, every day can be unpredictable, due to fluctuating muscle weakness and fatigue. They may also experience severe exacerbations that can be life-threatening. Many still experience suboptimal disease control, whether from waning of therapeutic effect, inadequate response or high treatment burden,” said Tuan Vu, M.D., Professor of Neurology at the University of South Florida Morsani College of Medicine, Division Director for Neuromuscular Medicine and EMG Laboratories, and a global principal investigator of the NIMBLE trial. “In the Phase 3 NIMBLE trial, Livsayis delivered rapid, deep disease control – maintained through the end of dosing intervals – and offers a four-times-a-year subcutaneous dosing schedule. These results highlight how a first-of-its-kind approach can address a key driver of disease and provide a compelling treatment option.”

The FDA approval was based on results from the Phase 3 NIMBLE trial. Livsayis demonstrated the following least square mean change from baseline:

  • 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score
    at 24 weeks (0.4 standard error [SE]) compared to a 2.2-point improvement with placebo (0.5 SE). This corresponded to a placebo-adjusted improvement of 2.3 points (p=0.0005). MG-ADL is a clinician-administered patient-reported assessment of daily functions impacted by gMG, such as talking, chewing, swallowing, breathing, vision and mobility. The proportion of MG-ADL responders with at least 3-point improvement at week 24 was greater for Livsayis (76.6%) compared to placebo (44.1%, p<0.001).
  • 4.2-point improvement in Quantitative Myasthenia Gravis (QMG) total score
    at 24 weeks (0.6 SE) compared to a 1.5-point improvement with placebo (0.7 SE), corresponding to a placebo-adjusted improvement of 2.8 points (p=0.0015). QMG is a clinician-administered assessment of muscle function, including vision, speaking/swallowing, breathing and limb mobility. The proportion of QMG responders with at least a 5-point improvement at week 24 was greater for Livsayis (48.4%) compared to placebo (19.0%, p<0.001).
  • Rapid onset of clinically meaningful benefit in MG-ADL (2.5 points), with improvements seen as early as two weeks of starting treatment that deepened over time.
  • Sustained disease control and symptom relief through 24 weeks, with MG-ADL scores maintained and no indication of waning efficacy.

The prescribing information for Livsayis includes a Boxed Warning for serious meningococcal infections in addition to warnings and precautions for other serious infections, consistent with other FDA-approved medicines that reduce C5 activity. The most common adverse reactions (≥5%) in patients treated with Livsayis and more frequently than placebo were injection site reactions, viral infections and urinary tract infections. Livsayis is available only through a restricted program called the Livsayis Risk Evaluation and Mitigation Strategy (REMS), which is also consistent with other FDA-approved medicines that reduce C5 activity. Details of the Important Safety Information are included below.

“Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalized myasthenia gravis who need effective disease control without a heavy treatment burden,” said George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer of Regeneron. “As Regeneron’s first approved siRNA therapy, this approval marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases.”

“Individuals living with gMG experience profound muscle weakness that can affect how they talk, see, breathe and move, and with it their ability to carry out everyday activities,” said Samantha Masterson, President & CEO, Myasthenia Gravis Foundation of America. “This approval is a positive milestone for the gMG community, reflecting continued progress on outcomes that matter most to patients. With Livsayis, those living with generalized myasthenia gravis have a new option that may help maintain disease control while reducing the burden treatment can place on daily life.”

Regeneron is committed to supporting people living with rare diseases and ensuring patients who have been prescribed Livsayis access to their medication. Regeneron’s myRARE™ program offers resources to help patients and healthcare providers, including product information, insurance benefit verification, and information about potential financial support. To learn about myRARE, visit myRARE.com or call 1-833-4my-RARE (1-833-469-7273).

A regulatory submission for Livsayis for the treatment of gMG is currently under review in the European Union, with a decision anticipated in the second half of 2027. Regulatory submissions are planned in additional markets, including Japan.

About gMG

gMG is a rare, chronic autoimmune disease characterized by unpredictable, debilitating and potentially life-threatening muscle weakness. In the most common form of the disease, abnormal anti-AChR antibodies activate the complement system including C5, disrupting communication between nerves and muscles, which contributes to damage at the neuromuscular junction. For these patients, the disease affects muscles throughout the body, resulting in extreme fatigue and difficulties with facial expression, speech, swallowing, mobility, breathing as well as severe exacerbations, including myasthenic crisis that can impair breathing to the point of requiring hospitalization. Worldwide, an estimated 150 to 200 out of every million people have MG. In the U.S., the disease impacts approximately 85,000 people.

About Livsayis

Livsayis is the first approved siRNA therapy for gMG and the only gMG treatment FDA-approved to be administered subcutaneously four times per year (every three months).

Livsayis is a complement C5-directed siRNA that degrades the messenger RNA (mRNA) that encodes the C5 protein, thereby blocking C5 production, reducing circulating levels of C5 and inhibiting terminal complement activation, a key driver of AChR-positive gMG.

Regeneron is solely responsible for the development, manufacturing, and commercialization of Livsayis through a worldwide licensing agreement with Alnylam.

About the NIMBLE trial

NIMBLE is the largest global, interventional gMG trial conducted to date. In this ongoing Phase 3, randomized, double-blind, placebo-controlled trial, Livsayis is being evaluated in patients with anti-AChR antibody-positive gMG who can continue background immunosuppressants based on the investigator’s discretion. Participants were randomized to receive one of four subcutaneous regimens: Livsayis every three months; a combination of Livsayis and a C5-inhibiting monoclonal antibody every 4 weeks; C5-inhibiting monoclonal antibody every 4 weeks; or placebo every 4 weeks.

The primary endpoint assessed changes in the MG-ADL total score from baseline to week 24. The MG-ADL scale is an eight-question clinician-administered, patient-reported tool that measures how gMG affects aspects of daily life and provides a total score ranging from 0 to 24. The key secondary endpoint was the change from baseline in QMG total score at week 24. The QMG is a clinician-administered 13-item standardized assessment evaluating muscle function that provides a total score ranging from 0 to 39. In both MG-ADL and QMG, a higher total score indicates greater disease severity, and a larger reduction in total score indicates greater improvement in disease symptoms and better treatment effect.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about LIVSAYIS?

LIVSAYIS is a medicine that affects part of your immune system. LIVSAYIS may lower the ability of your immune system to fight certain infections.

  • LIVSAYIS increases your chance of getting serious meningococcal infections caused by Neisseria meningitidis bacteria. Meningococcal infections may quickly become life-threatening or cause death if not recognized and treated early.
    • You must complete your meningococcal vaccines at least 2 weeks before your first dose of LIVSAYIS.
    • If you have not completed your meningococcal vaccines, and LIVSAYIS must be started right away, you should receive the required vaccines as soon as possible.
    • If you have not been vaccinated and LIVSAYIS must be started right away, you must also receive antibiotics.
    • If you had a meningococcal vaccine in the past, you might need additional vaccination before starting LIVSAYIS. Your healthcare provider will decide if you need additional meningococcal vaccination.
    • Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical help right away if you get any of these signs and symptoms of a meningococcal infection: fever, fever and a rash, fever with high heart rate, headache with nausea or vomiting, headache and a fever, headache with a stiff neck or stiff back, confusion, muscle aches with flu-like symptoms, or eyes sensitive to light

Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 12 months after your last LIVSAYIS dose. Your risk of meningococcal infection may continue for several months after your last dose of LIVSAYIS. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.

LIVSAYIS is only available through a program called the LIVSAYIS Risk Evaluation and Mitigation Strategy (REMS). Before you can receive LIVSAYIS, your healthcare provider must: enroll in the LIVSAYIS REMS program; counsel you about the risk of serious meningococcal infections; give you the Patient Guide that explains your risk of serious meningococcal infections; give you a Patient Safety Card that has important information about the signs and symptoms of meningococcal infections; make sure that you are vaccinated against serious infections caused by meningococcal bacteria, and that you receive antibiotics if you need to start LIVSAYIS right away and you are not up-to-date on your vaccines.

LIVSAYIS may
also
increase the risk of other types of serious infections
especially those caused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Certain people may be at risk of serious infections with gonorrhea. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and regular testing.

Call your healthcare provider right away if you have new signs or symptoms of infection.

Who should not receive LIVSAYIS?

  • Do not receive LIVSAYIS if you have a serious meningococcal infection when you are starting LIVSAYIS treatment.

Before you receive LIVSAYIS, tell your healthcare provider about all your medical conditions, including if you:

  • Have an infection or fever
  • Are pregnant or plan to be pregnant. It is not known whether LIVSAYIS will harm your unborn baby
  • Are breastfeeding or plan to breastfeed. It is not known if LIVSAYIS passes into your breast milk

Tell your healthcare provider about medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take and the vaccines you receive. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

The most common side effects in people with gMG treated with LIVSAYIS include: injection site reactions, viral infections and urinary tract infections.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of LIVSAYIS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full

Prescribing Information

, including Boxed WARNING, and

Medication Guide

for LIVSAYIS.

What is LIVSAYIS?

LIVSAYIS is a prescription medicine used to treat a disease called generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if LIVSAYIS is safe and effective in children.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Livsayis™ (cemdisiran) for the treatment of generalized myasthenia gravis (“gMG”); uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products (such as Livsayis) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products (such as Livsayis); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Livsayis) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products (such as Livsayis) and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) as well as Regeneron’s license agreement with Alnylam Pharmaceuticals, Inc. referenced in this press release, to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of the Company or other parties and pending or future litigation or patent office proceedings relating thereto (including without limitation patent litigation and other related proceedings relating to Regeneron’s Products), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended September 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (

https://investor.regeneron.com

) and its LinkedIn page (

https://www.linkedin.com/company/regeneron-pharmaceuticals

).


Contacts:
 
Media Relations

Tammy Allen

Tel: +1 914-306-2698
[email protected]
Investor Relations

Mark
Hudson

Tel: +1 914-847-3482
[email protected]